Back to Search
Start Over
Mutant dominant-negative rhodopsin ∆I256 causes protein aggregates degraded via ERAD and prevents normal rhodopsin from proper membrane trafficking.
- Source :
-
Frontiers in molecular biosciences [Front Mol Biosci] 2024 May 17; Vol. 11, pp. 1369000. Date of Electronic Publication: 2024 May 17 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Dominant mutations in the rhodopsin gene ( Rho ) contribute to 25% of autosomal dominant retinitis pigmentosa (adRP), characterized by photoreceptor loss and progressive blindness. One such mutation, Rho <superscript> ∆I256 </superscript> , carries a 3-bp deletion, resulting in the loss of one of two isoleucines at codons 255 and 256. Our investigation, using recombinant expression in HEK293 and COS-7 cells, revealed that Rho <superscript> ∆ I256</superscript> , akin to the known adRP mutation Rho <superscript>P23H</superscript> , induces the formation of rhodopsin protein (RHO) aggregates at the perinuclear region. Co-expression of Rho <superscript> ∆I256 </superscript> or Rho <superscript> P23H </superscript> with wild-type Rho <superscript> WT </superscript> , mimicking the heterozygous genotype of adRP patients, demonstrated the dominant-negative effect, as all isoforms were retained in perinuclear aggregates, impeding membrane trafficking. In retinal explants from WT mice, mislocalization of labeled adRP isoforms at the outer nuclear layer was observed. Further analysis revealed that RHO <superscript>∆I256</superscript> aggregates are retained at the endoplasmic reticulum (ER), undergo ER-associated degradation (ERAD), and colocalize with the AAA-ATPase escort chaperone valosin-containing protein (VCP). These aggregates are polyubiquitinated and partially colocalized with the 20S proteasome subunit beta-5 (PSMB5). Pharmacological inhibition of proteasome- or VCP activity increased RHO <superscript>∆I256</superscript> aggregate size. In summary, RHO <superscript>∆I256</superscript> exhibits dominant pathogenicity by sequestering normal RHO <superscript>WT</superscript> in ER aggregates, preventing its membrane trafficking and following the ERAD degradation.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2024 Cao, Dahlen, Sen, Beyer, Leonhard, Kilger, Arango-Gonzalez and Ueffing.)
Details
- Language :
- English
- ISSN :
- 2296-889X
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- Frontiers in molecular biosciences
- Publication Type :
- Academic Journal
- Accession number :
- 38828393
- Full Text :
- https://doi.org/10.3389/fmolb.2024.1369000